Aficamten - Cytokinetics
Alternative Names: BAY-3723113; CK 3773274; CK-274Latest Information Update: 22 Jun 2025
At a glance
- Originator Cytokinetics
- Developer Corxel Pharmaceuticals; Cytokinetics
- Class Amides; Cardiovascular therapies; Heart failure therapies; Indenes; Oxadiazoles; Pyrazoles; Small molecules
- Mechanism of Action Cardiac myosin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preregistration Hypertrophic cardiomyopathy
Most Recent Events
- 20 Jun 2025 Bayer plans a phase III CAMELLIA-HCM trial for Hypertrophic cardiomyopathy in Japan (PO) (NCT07023341)
- 13 May 2025 Adverse events and efficacy data from phase III MAPLE-HCM trial in Hypertrophic cardiomyopathy released by Cytokinetics
- 01 May 2025 FDA assigns PDUFA action date of (26/12/2025) for Aficamten for hypertrophic cardiomyopathy